Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2011

View Archived Issues

Novartis presents key developments of third quarter 2011

Phase II data on FG-4592 presented at Kidney Week

Phase IIa trial assesses systemic ammonia scavenger in liver disease

Fixed doses selected for further phase II sifalimumab testing in SLE

Analyses highlight importance of patient selection for diabetic nephropathy therapy

XOMA broadens phase III program for gevokizumab

Verona Pharma's RPL-554 demonstrates bronchodilation in phase IIa study

Data reported on immunotherapy for use in liver transplantation for chronic hepatitis C

Merck & Co. discloses new protein kinase inhibitors

Novel glutaminyl-peptide cyclotransferase inhibitors synthesized by Probiodrug

SymBio begins Japanese phase II trial of SyB L-0501 for new indication

Boehringer Ingelheim presents novel PDK1 inhibitors

Seikagaku to begin phase III study of enzyme therapy in lumbar disc herniation

New cytochrome P450 19A1 inhibitors patented in U.S.

Daiichi Sankyo licenses protein kinase inhibitor from ArQule for phase I development

Phase I and II studies commence for BMS-927711 in migraine

Canadian organization prepares novel protein kinase inhibitors

Lundbeck and Otsuka collaborate on products for psychiatric conditions

Japanese encephalitis vaccine approved in India

NeuroDerm reports phase II ND-0611 data

BioDelivery Sciences begins dose-finding BNX-102 study

FDA releases safety communication on Trilipix

Anacor advances phase III AN-2690 study

FDA grants orphan drug status to Santen product in noninfectious uveitis

Napo cites breach of contract in termination of agreement with Salix

Dosing complete in phase II trial of ASP-7373

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...